Premature ovarian failure
Conditions
Interventions
Control group:Femton (produced by Abbott Healthcare Products B.V., registration number H20150345)
Treatment Group:(Abbott Healthcare Products B.V.,H20150345) and moxibustion at DU4 and RN8 points
Sponsors
Yueyang Hospital of Intrgrated Traditional Chinese and Western Medicine, Shanghai University of Trditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Correspond to diagnosis standards of western medicine and traditional Chinese medicine (TCM) syndrome of Spleen-kidney Yang deficiency type; 2.Aged 18-40; 3.Those who voluntarily join this study and sign the informed consent form, and are able to comply with the study treatment requirements.
Exclusion criteria
Exclusion criteria: 1.Patients with primary amenorrhea; 2.Patients whose diminished ovarian reserve are caused by congenital reproductive organs dysplasia or genital injury; 3.Patients who have been diagnosed with tumors or have undergone radiotherapy and chemotherapy; 4.Patients whose amenorrhea are caused by thyroid, ovarian functional tumors, central nervous system, hypothalamus and other system organ diseases; 5.Patients who can easily get cicatrix and are allergic to the ingredients of traditional Chinese medicine; 6.Patients who are suffering from severe primary diseases such as heart, liver, brain, kidney and hematopoietic system; 7.Mentally disabled patients; 8.Patients with contraindications to Femton; 9.Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The modified Kupperman scale;Follicle-Stimulating Hormone;Luteinizing Hormone;Estradiol;Anti-Müllerian Hormone; | — |
Countries
China
Contacts
Public ContactBao Chunling
Yueyang Hospital of Intrgrated Traditional Chinese and Western Medicine, Shanghai University of Trditional Chinese Medicine
Outcome results
None listed